Colorectal cancer (CRC) screening is a critical topic, and the SCREESCO trial sheds light on some fascinating insights. Imagine a world where we can detect cancer earlier and potentially save more lives. That's the promise of CRC screening, but it's not without its challenges and trade-offs. Let's dive into this groundbreaking study.
The SCREESCO trial compared two real-world screening strategies: a one-time primary colonoscopy and repeated fecal immunochemical testing (FIT) with colonoscopy reserved for positive results, against the usual care of no screening invitation. The goal? To clarify the benefits of early detection and the short-term risks associated with diagnostic procedures.
But here's where it gets controversial... Many guidelines recommend CRC screening, but the devil is in the details. While colonoscopy is often seen as the gold standard, many organized programs opt for FIT, repeated every 1-2 years, followed by colonoscopy only if the FIT result is positive. So, which approach is better?
The SCREESCO trial, conducted in Sweden, aimed to fill this evidence gap by randomizing participants across 18 regions. The study design was pragmatic and population-based, with a focus on the 'diagnostic phase' - the critical period when screening procedures and follow-up workups occur.
The results are intriguing. After a median follow-up of almost 5 years, the overall CRC incidence didn't show a clear reduction compared to usual care. However, there was a significant shift in the stage at which cancers were diagnosed. Invitation to screening, especially primary colonoscopy, led to a higher detection rate of early-stage CRC (stage I-II). This stage shift was most pronounced in the first year after randomization, aligning with the timing of screening procedures.
And this is the part most people miss... Later-stage CRC (stage III-IV) became less frequent over time, especially in the FIT×2 arm. This suggests a potential long-term benefit, possibly due to earlier detection and prevention effects. However, the net incidence reduction wasn't visible within the first 5 years.
Safety and adverse events were also a key focus. Across both intervention strategies, GI and cardiovascular event rates were slightly higher during the first year but became more similar to controls later on. FIT×2 showed specific safety signals, with higher rates of venous thromboembolism and bleeding-related GI events compared to controls.
The SCREESCO trial provides valuable insights into the benefits and harms of CRC screening strategies. While invitation to screening increased early-stage CRC diagnoses, the long-term impact and potential life-saving benefits will become clearer with extended follow-up. The trial's ultimate endpoint, CRC mortality, will be reported in the final analysis, providing a definitive answer to the question of which screening strategy saves more lives.
So, what do you think? Do the benefits of early detection outweigh the short-term risks? Share your thoughts and let's discuss the implications of this groundbreaking study!
